Imaging and Other Biomarkers in Early Clinical Studies: One Step at a Time or Re-Engineering Drug Development?
- 20 August 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (24), 5417-5419
- https://doi.org/10.1200/jco.2005.05.907
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I StudyJournal of Clinical Oncology, 2005
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Functional Imaging in Phase I Studies: Decorations or Decision Making?Journal of Clinical Oncology, 2003
- CAST: Implications for drug developmentClinical Pharmacology & Therapeutics, 1990